Trials / Completed
CompletedNCT04887948
Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2
A PHASE 3, RANDOMIZED, DOUBLE BLIND TRIAL TO DESCRIBE THE SAFETY AND IMMUNOGENICITY OF 20 VALENT PNEUMOCOCCAL CONJUGATE VACCINE WHEN COADMINISTERED WITH A BOOSTER DOSE OF BNT162b2 IN ADULTS 65 YEARS OF AGE AND OLDER
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 570 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Accepted
Summary
Study of the safety and immunogenicity of 20vPnC and a booster dose of BNT162b2 administered at the same visit or each vaccine given alone
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | 20-valent pneumococcal conjugate vaccine (20vPnC) | 20-valent pneumococcal conjugate vaccine (20vPnC) |
| BIOLOGICAL | BNT162b2 | RNA-based SARS-CoV-2 vaccine (BNT162b2) |
| OTHER | Saline | Normal saline for injection |
Timeline
- Start date
- 2021-05-20
- Primary completion
- 2021-12-08
- Completion
- 2021-12-08
- First posted
- 2021-05-14
- Last updated
- 2022-12-14
- Results posted
- 2022-12-14
Locations
27 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04887948. Inclusion in this directory is not an endorsement.